> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lifecore Biomedical Fixes November 4 Record Date For Vote On Hazel Merger Sub Deal
- URL: https://www.bullished.co/lifecore-biomedical-fixes-november-4-record-date-for-vote-on-hazel-merger-sub-deal-83e3ce62/
- Published: 2026-10-20T20:35:59.000Z
- Updated: 2026-10-28T19:32:14.000Z
- Description: Holders of record at the close of business on November 4 can vote at the special meeting on the merger agreement, an 8-K says.
- Author: Matteo Parrino
- Tags: Deals, LFCR, Industry: Healthcare

Lifecore Biomedical's board [set November 4, 2026](https://www.sec.gov/Archives/edgar/data/0001005286/000100528626000040/lfcr-20261016.htm?ref=bullished.co) as the record date, the cutoff for who can vote at a special stockholder meeting on its merger, according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) the company filed Tuesday. The board made the decision on Friday, October 16.

## What the 8-K says

Only holders of record as of the close of business on November 4 will receive notice of the special meeting and be entitled to vote at it. The meeting is meant to approve, among other things, adoption of the merger agreement and the merger it contemplates.

The filing says Lifecore Biomedical signed that agreement on September 27, 2026, with Lifecore Inc. and Hazel Merger Sub, Inc. It describes the signing as previously disclosed.

The filing is an [Item 8.01 report](https://www.sec.gov/Archives/edgar/data/0001005286/000100528626000040/lfcr-20261016.htm?ref=bullished.co), the form's catch-all section for other events. It is signed by Chief Financial Officer Ryan D. Lake and dated October 20, 2026.

## What it changes for holders

If you own the stock, the date that matters is the record date. Shares held at the close of business on November 4 carry the vote; the filing does not say when the meeting itself will take place.

LFCR shares closed at $6.37 in Tuesday's session, down 0.31%, before the filing was accepted at 4:30 p.m. ET.

## What to watch

Under the merger agreement, the company will file a preliminary proxy statement with the SEC for the special meeting. It also intends to file a definitive proxy statement.

The company urges investors to read those documents when they become available, saying they will contain important information. Copies will be free on the SEC's website and through the investor relations section of the company's site.

The preliminary proxy statement is the next document due, and it is where holders should look for the meeting date.

Learn

- [Item 8.01: other events →](https://www.bullished.co/learn/8-k-items-explained/#item-801-other-events)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — LIFECORE BIOMEDICAL, INC. \\DE\\ (LFCR)](https://www.sec.gov/Archives/edgar/data/0001005286/000100528626000040/lfcr-20261016.htm?ref=bullished.co) — SEC EDGAR